28 October 2021 | News
To tackle antimicrobial resistance including new capabilities in computational biology
image credit- shutterstock
The International Vaccine Institute (IVI) in South Korea and the Joint European Disruptive Initiative (JEDI) have signed a Memorandum of Understanding (MoU) to establish a collaborative relationship.
Both organizations are dedicated to advancing innovations in health and science. IVI and JEDI will explore many cooperation routes, in particular around innovative approaches to zoonoses, infectious diseases and in addressing the global threat of antimicrobial resistance (AMR).
Additionally, the MOU invites Dr. Jerome Kim, Director General of IVI, Francois Belin, Chief Operating Officer of IVI, and Dr Anh Wartel, Deputy Director General of IVI’s Clinical, Assessment, Regulatory, and Evaluation Unit, to participate in JEDI’s International Partners Advisory Board.
The signing ceremony took place at the French National Centre for Scientific Research (CNRS) in Paris, France with Dr Jerome Kim and André Loesekrug-Pietri, Chairman of JEDI.
Dr Kim said “With JEDI’s common interest in combatting existing and future zoonoses as well as global AMR, we look forward to collaborating on solutions to this threat to humanity.”
Loesekrug-Pietri said “As we did for the JEDI GrandChallenge against Covid-19, we want to introduce disruptive approaches to other fields of healthcare, with boldness and a total focus on excellence. As a first concrete step, we are excited to work with IVI to tackle antimicrobial resistance, including new capabilities in computational biology.”